单位：[1]Department of Thoracic Surgery, China-Japan Friendship Hospital, Beijing, China[2]Department of Information Management, China-Japan Friendship Hospital, Beijing, China
Background: Lung cancer claims more lives than any other cancer worldwide. Lung adenocarcinoma (LUAD) accounts for approximately 40% of all lung cancers. Members of the Transducin-like Enhancer of split (TLE) protein family repress transcription through multiple mechanisms; however, their prognostic value in LUAD is still unclear. Methods: A dataset from The Cancer Genome Atlas was used to analyze the relationship between the expression of TLE family members and outcomes of LUAD. The expression of TLE family members in 59 normal and 513 tumor samples in the TCGA dataset was selected. For paired analysis, 57 normal and 57 tumor paired tissues were selected. Gene Ontology (GO) term and Reactome pathway enrichment analyses of the TLE family members were performed. Progression-free survival (PFS) and overall survival (OS) served as endpoints in this study. All statistical analyses were performed with R 3.6.0. Results: The expression levels of TLE family proteins differed between 59 normal and 513 tumor samples. High TLE1 and low TLE2 levels were associated with poor progression-free and OS (all P<0.050). Multivariate analysis demonstrated that high TLE1 expression and low TLE2 expression were independent risk factors for a poor outcome in LUAD. Moreover, the combined expression of these two proteins was a good tool for prognostication. Conclusions: High TLE1 expression and low TLE2 are independent adverse prognostic factors in LUAD and can serve as prognostic biomarkers.
基金：
research and demonstration application of clinical diagnosis and treatment technology in Beijing capital city [Z191100006619008]
第一作者单位：[1]Department of Thoracic Surgery, China-Japan Friendship Hospital, Beijing, China
通讯作者：
通讯机构：[1]Department of Thoracic Surgery, China-Japan Friendship Hospital, Beijing, China[2]Department of Information Management, China-Japan Friendship Hospital, Beijing, China[*1]Department of Information Management, China-Japan Friendship Hospital, No. 2, Yinghua East Road, Chaoyang, Beijing 100029, China.[*2]Department of Thoracic Surgery, China-Japan Friendship Hospital, No. 2, Yinghua East Road, Chaoyang, Beijing 100029, China.
推荐引用方式(GB/T 7714)：
Ma Qianli,Xiao Fei,Hao Yang,et al.The prognostic role of the Transducin-like Enhancer of split protein family in lung adenocarcinoma[J].TRANSLATIONAL LUNG CANCER RESEARCH.2021,10(7):3251-+.doi:10.21037/tlcr-21-582.
APA：
Ma, Qianli,Xiao, Fei,Hao, Yang,Song, Zhiyi,Zhang, Jin...&Liu, Deruo.(2021).The prognostic role of the Transducin-like Enhancer of split protein family in lung adenocarcinoma.TRANSLATIONAL LUNG CANCER RESEARCH,10,(7)
MLA：
Ma, Qianli,et al."The prognostic role of the Transducin-like Enhancer of split protein family in lung adenocarcinoma".TRANSLATIONAL LUNG CANCER RESEARCH 10..7(2021):3251-+
